Grace Therapeutics, Inc.
GRCE
$3.21
$0.103.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.36M | 636.00K | -4.16M | -3.43M | -2.62M |
| Total Depreciation and Amortization | 2.00K | 2.00K | 2.00K | 2.00K | 1.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 789.00K | -3.53M | 733.00K | -1.01M | -1.88M |
| Change in Net Operating Assets | 770.00K | -66.00K | -695.00K | 203.00K | 901.00K |
| Cash from Operations | -1.80M | -2.95M | -4.12M | -4.24M | -3.60M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 15.00K | 0.00 | -15.00K |
| Cash from Investing | -- | 0.00 | 15.00K | 0.00 | -15.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 15.00M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -327.00K | -967.00K | -- | -- | -- |
| Cash from Financing | -327.00K | 14.03M | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.13M | 11.08M | -4.10M | -4.24M | -3.61M |